Trials / Completed
CompletedNCT00343733
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
A 12-Week Open-Label Study With 3 Within-Patient Double-Blind Placebo-Controlled Periods to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (planned)
- Sponsor
- Cephalon · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy and safety of OraVescent fentanyl treatment compared to placebo treatment monthly over a 12-week treatment period in alleviating breakthrough pain (BTP) in opioid-tolerant patients with noncancer-related chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OraVescent Fentanyl |
Timeline
- Start date
- 2006-08-01
- Completion
- 2007-07-01
- First posted
- 2006-06-23
- Last updated
- 2014-05-09
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00343733. Inclusion in this directory is not an endorsement.